Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus METOPROLOL SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus METOPROLOL SUCCINATE.
COREG CR vs METOPROLOL SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors. Also suppresses renin release.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
25 to 100 mg orally once daily, titrated at weekly intervals as tolerated; maximum 400 mg/day
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Terminal elimination half-life: 3-7 hours. Twice-daily dosing (metoprolol succinate) provides stable beta-blockade over 24 hours due to extended-release formulation, not due to half-life.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Primarily renal (95% as metabolites, <5% unchanged). Three main metabolites: O-demethylated (active), α-hydroxylated (active), and O-demethylated and α-hydroxylated. Biliary/fecal excretion: <5%.
Category C
Category C
Beta-Blocker
Beta-Blocker